Menu
Back to Journals » Journal of Pain Research » Volume 9
The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development
Authors Fudin J, Pratt Cleary J, Schatman M
Received 4 March 2016
Accepted for publication 4 March 2016
Published 23 March 2016 Volume 2016:9 Pages 153—156
DOI https://doi.org/10.2147/JPR.S107794
Checked for plagiarism Yes
Jeffrey Fudin,1 Jacqueline Pratt Cleary,2 Michael E Schatman3
1Western New England University College of Pharmacy, Springfield, MA, 2Stratton VA Medical Center, Albany, NY, 3US Pain Foundation, Bellevue, WA, USA
With the opioid-misuse and -abuse problem on the rise, pain practitioners and lawmakers are scrambling for strategies to help mitigate opioid risks. Approaches include opioid-treatment agreements, urine drug testing, prescription-monitoring programs, assorted validated risk-assessment tools for abuse/misuse and opioid-induced respiratory depression (OIRD), biopsychosocial support, and other strategies.1–3 Nonopioid pain therapies should be considered and maximized prior to initiating opioid treatment; however, in some cases opioids are the optimal choice for both noncancer and cancer-related pain syndromes.4
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.